Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

252.90 -0.10 (-0.04%)
Delayed Quote Updated: 11:16 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
A Look Ahead: Ascendis Pharma's Earnings Forecast ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Looking Into Ascendis Pharma AS's Recent Short Interest ↗
 
Via Benzinga
News headline image
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗
Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum. 
Via Chartmill
News headline image
What Does the Market Think About Ascendis Pharma AS? ↗
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which... 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market... 
Via Benzinga
News headline image
How Do Investors Really Feel About Ascendis Pharma? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Peering Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum ↗
Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance. 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Is Ascendis Pharma Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of Ascendis Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
Ascendis (ASND) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
What's Driving the Market Sentiment Around Ascendis Pharma? ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Ascendis Pharma? ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria ↗
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing? 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.